Crinetics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 290
- Market Cap
- $4.3B
- Website
- http://www.crinetics.com
- Introduction
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Clinical Trials
54
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
- Conditions
- Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT07159841
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
- Conditions
- Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT07144163
- Locations
- 🇦🇺
Crinetics Study Site, Nedlands, Western Australia, Australia
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Conditions
- Neuroendocrine TumorsNeuroendocrine NeoplasmSST2-positive Neuroendocrine Neoplasms
- Interventions
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT07129252
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Conditions
- Carcinoid SyndromeCarcinoidCarcinoid TumorCarcinoid Tumor of IleumCarcinoid Tumor of CecumCarcinoid Tumor of LiverCarcinoid Tumor of PancreasCarcinoid Syndrome DiarrheaCarcinoid Intestine Tumor
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT07087054
- Locations
- 🇺🇸
Yale University - New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Winshop Cancer Institute - Emory University, Atlanta, Georgia, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
- Conditions
- Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
- Interventions
- Drug: atumelnant (CRN04894)
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06712823
- Locations
- 🇺🇸
Crinetics Study Site, Minneapolis, Minnesota 55454, Minneapolis, Minnesota, United States
🇬🇧Crinetics Study Site, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- Next
News
FDA Sets Q3 2025 Approval Dates for Three Breakthrough Therapies Targeting Rare Diseases
The FDA has established PDUFA target action dates for three promising therapies in Q3 2025: sepiapterin for phenylketonuria (July 29), apitegromab for spinal muscular atrophy (September 22), and paltusotine for acromegaly (September 25).